

# TABLE OF CONTENTS

|                           |   |
|---------------------------|---|
| <b>Hematology I</b> ..... | 1 |
| Hematology I Panel .....  | 3 |

## Factor Products

*By Cassie A. Barton, Pharm.D., BCPS, BCCCP; and Jesse Bierman, Pharm.D., BCCCP*

|   |    |
|---|----|
| Introduction .....                            | 7  |
| Von Willebrand Disease .....                  | 7  |
| Hemophilia A and B .....                      | 12 |
| Future Therapies .....                        | 19 |
| Anticoagulant Reversal Strategies .....       | 19 |
| General Treatment and Assessment Tenets ..... | 19 |
| Conclusion .....                              | 23 |
| References .....                              | 23 |
| Self-Assessment Questions .....               | 26 |

## Thrombocytopenia

*By Amber H. Diaz, Pharm.D., BCOP; and Kelli M. Leong, Pharm.D., BCPS*

|  |    |
|--|----|
| Introduction .....                                 | 29 |
| Clinical Guidelines .....                          | 30 |
| Immune Thrombocytopenia .....                      | 30 |
| Syndromes of Thrombotic Microangiopathy .....      | 40 |
| Drug-Induced Thrombocytopenia .....                | 44 |
| Platelet Transfusions .....                        | 45 |
| Clinical Considerations with Anticoagulation ..... | 45 |
| Conclusion .....                                   | 46 |
| References .....                                   | 46 |
| Self-Assessment Questions .....                    | 49 |

|                           |    |
|---------------------------|----|
| <b>Immunology I</b> ..... | 53 |
| Immunology I Panel .....  | 55 |

## Systemic Lupus Erythematosus

*By Joshua Wiegel, Pharm.D., BCPS; and Janet M. Bramell, Pharm.D., BCPS, BCOP*

|                                    |    |
|------------------------------------|----|
| Introduction .....                 | 59 |
| Pathophysiology .....              | 60 |
| Diagnosis .....                    | 62 |
| Measures of Disease Activity ..... | 65 |

|  |    |
|--|----|
| Clinical Guidelines and Consensus Statements ..... | 68 |
| Pharmacotherapy .....                              | 70 |
| Lupus Nephritis .....                              | 76 |
| Conclusion .....                                   | 79 |
| References .....                                   | 79 |
| Self-Assessment Questions .....                    | 82 |

## Hematopoietic Stem Cell Transplantation

*By Alex Ganetsky, Pharm.D., BCOP; and Dragos Plesca, Pharm.D., Ph.D., BCOP*

|                                       |    |
|---------------------------------------|----|
| Introduction .....                    | 87 |
| Indications for Transplantation ..... | 89 |
| Complications of HCT .....            | 90 |
| Maintenance Therapy After HCT .....   | 95 |
| References .....                      | 97 |
| Self-Assessment Questions .....       | 99 |

|                         |     |
|-------------------------|-----|
| <b>Oncology I</b> ..... | 103 |
| Oncology I Panel .....  | 105 |

## New Therapies for Advanced NSCLC

*By Val R. Adams, Pharm.D., FCCP, BCOP; and Alison Palumbo, Pharm.D., MPH, BCOP*

|  |     |
|--|-----|
| Introduction .....                                   | 109 |
| Biopsy Methods and Mutational Findings .....         | 110 |
| Selecting Therapy .....                              | 111 |
| Response Evaluation .....                            | 119 |
| Toxicities and Management .....                      | 119 |
| Immune Toxicity Monitoring and Counseling Keys ..... | 124 |
| References .....                                     | 124 |
| Self-Assessment Questions .....                      | 127 |

## Breast Cancer

*By Alexandre Chan, Pharm.D., MPH, FCCP, BCPS, BCOP*

|   |     |
|---|-----|
| Introduction .....                                | 131 |
| Treatment of Early-Stage Breast Cancer .....      | 132 |
| Treatment of Locally Advanced Breast Cancer ..... | 136 |
| Treatment of Metastatic Breast Cancer .....       | 138 |
| Treatment of TNBC .....                           | 140 |

|   |     |
|---|-----|
| Novel Therapeutic Agents<br>for Breast Cancer ..... | 141 |
| Conclusion .....                                    | 147 |
| References .....                                    | 148 |
| Self-Assessment Questions .....                     | 150 |

|                          |     |
|--------------------------|-----|
| <b>Oncology II</b> ..... | 153 |
| Oncology II Panel .....  | 155 |

### **Skin Cancer**

*By Megan Reimann, Pharm.D., BCOP; and Susan M. Bullington,  
Pharm.D., BCOP*

|  |     |
|--|-----|
| Introduction .....                     | 159 |
| Treatment of Melanoma .....            | 161 |
| Treatment of Metastatic Melanoma ..... | 164 |
| Treatment of NMSC .....                | 173 |

|                                 |     |
|---------------------------------|-----|
| Conclusion .....                | 175 |
| References .....                | 176 |
| Self-Assessment Questions ..... | 179 |

### **Cancer Clinical Trials**

*By Ashley E. Glode, Pharm.D., BCOP; and Cindy L. O'Bryant,  
Pharm.D., BCOP, FCCP, FHOPA*

|  |     |
|--|-----|
| Introduction .....   | 183 |
| Oncology Clinical Trial End Points .....                       | 185 |
| Intervention and Treatment Clinical Trial Design .....         | 187 |
| Barriers to Participation in Oncology Clinical<br>Trials ..... | 197 |
| Selected Issues .....  | 199 |
| Conclusion .....   | 200 |
| References .....   | 201 |
| Self-Assessment Questions .....                                | 203 |